1-3 of 3
Patrick Burke
Close
Sort by
Journal Articles

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Keith Pratz, MD, Mark J. Levis, MD, John C Morris, MD, Trisha Wise-Draper, MD PhD, Moshe Levy, MD, Dale L. Bixby, Patrick Burke, MD, Daniela Hernandez, MD, Kate Stumpo, BA, Karuppiah Kannan, Emily Sheldon-Waniga, PhD, Shining Wang, MD, Steven Zhang, PhD, Yaping Shou, MD PhD, Jessica K. Altman, MD, Jason Kaplan, MD, Olga Frankfurt, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2622.
https://doi.org/10.1182/blood.V130.Suppl_1.2622.2622
Published: 2017
Journal Articles

Pharmacokinetics-Based Modification of Intravenous Pegylated Asparaginase Dosing in the Context of a “Pediatric-inspired” Protocol in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Dan Douer, MD, Ibrahim Aldoss, MD, Matthew A Lunning, DO, Laleh Ramezani, BSc, Patrick Burke, MD, Lisa Mark, PA, Janice Vrona, PA-C, Jae H. Park, MD, Martin S Tallman, MD, Vinod Pullarkat, MD, Ann M Mohrbacher, MD, Vassilos I Avramis, PhD
Journal: Blood
Blood (2012) 120 (21): 1495.
https://doi.org/10.1182/blood.V120.21.1495.1495
Published: 2012
Journal Articles

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

Olatoyosi M Odenike, John E. Godwin, Koen Van Besien, Dezheng Huo, Dorie Sher, Patrick Burke, Scott E. Smith, Margaret Green, Julia Melnick, James L Wade, Eric P. Lester, Rebecca B. Klisovic, Maria R. Baer, Richard A Larson, Wendy Stock
Journal: Blood
Blood (2008) 112 (11): 2809.
https://doi.org/10.1182/blood.V112.11.2809.2809
Published: 2008